http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
수직형 다엽 콜리메이터의 방사선 조사면 크기 결정을 통한 유용성 연구
이창열,손기홍,신상훈,박승우,이동한,정해조,최문식,오원용,김금배,양광모,지영훈,Lee, Chang-Yeol,Son, Ki-Hong,Shin, Sang-Hun,Park, Seung-Woo,Lee, Dong-Han,Jung, Hai-Jo,Choi, Mun-Sik,Oh, Won-Young,Kim, Kum-Bae,Yang, Gwang-Mo,Ji, Young-Hoo 한국의학물리학회 2011 의학물리 Vol.22 No.1
본 연구에서는 제작한 수직형 다엽 콜리메이터를 이용하여 방사선치료에 사용되는 Co-60 감마선 및 6 MV 엑스선의 조사면 크기와 모양을 결정하고 동일한 모양 및 크기의 조사면을 납차폐체로 결정하여 방사선 조사면 내 선량분포 특성을 상호 분석하여 수직형 다엽 콜리메이터의 방사선 조사면 크기 결정에 관한 유용성을 평가하였다. 이를 위해 이온전리함, 유리선량계, 방사선크로믹 필름을 사용하여 선량측정 실험을 수행하였다. Co-60 감마선과 6 MV 엑스선에 대하여 기준조사면의 이온전리함 측정결과 수직형 다엽 콜리메이터의 빔 중심축 선량값이 납차폐체의 선량값보다 각각 5.1%, 4.2% 높게 측정되었다. 그리고 Co-60 감마선에 대한 4개 조사면(기준 조사면, 원형, 삼각형, 십자형)의 유리선량계 측정 결과는 수직형 다엽 콜리메이터의 선량값이 납차폐체의 선량값보다 각각 2.2%, 7.8%, 7.2%, 4.0% 높게 측정되었고, 6 MV 엑스선에 대하여는 수직형 다엽 콜리메이터의 선량값이 납차폐체의 선량값보다 각각 6.7%, 6.2%, 3.8%, 6.2% 높게 측정되었다. 방사선크로믹 필름에서 차폐체의 선량분포곡선 중 최대선량의 80%에서 20%까지의 거리를 나타내는 반음영 크기는 모든 조사면에서 수직형 다엽 콜리메이터의 반음영 크기가 납차폐체보다 Co-60의 경우 2.0~3.5 mm, 6 MV 엑스선의 경우 0.5~1.0 mm 작게 나타났으며 이는 제작한 수직형 다엽 콜리메이터가 임상에 사용되었을 때 반음영의 크기를 납차폐체보다 줄일 수 있음으로써 치료 조사면적 결정시 차폐물의 반음영으로 생기는 방사선치료체적(Treatment Volume, TV)을 최소화시킬 수 있는 장점이 있으리라 판단된다. 아울러 2차원 및 3차원 방사선치료 시 본 다엽 콜리메이터를 이용하여 다양한 방사선치료 조사면을 간편하게 결정하여 사용할 수 있으리라 생각된다. The purpose of this study was to evaluate feasibility of Vertical Multileaf Collimator for determination of irradiation size using Vertical Multileaf Collimator and lead block to determine 4 different irradiation shape in case of Co-60 gamma-ray and 6 MV X-ray. We chose ion chamber, glass dosimeter and EBT chromic film to compare with Vertical Multileaf Collimator results and lead block results. In case of Co-60 gamma-ray and 6 MV X-ray, the central axis point dose normalized at reference field of lead block with ion chamber results for Vertical Multileaf Collimator were estimated higher than lead block about 5.1%, 4.2%. In case of Co-60 gamma-ray, the central axis point dose normalized at reference field of lead block with glass dosimeter results for Vertical Multileaf Collimator were estimated higher than lead block about 2.2%, 7.8%, 7.2%, 4.0% for reference, circle, triangle, cross field, respectively. In case of 6 MV X-ray, the central axis point dose normalized at reference field of lead block with glass dosimeter results for Vertical Multileaf Collimator were estimated higher than lead block about 6.7%, 6.2%, 3.8%, 6.2% for reference, circle, triangle, cross field, respectively. The results of EBT chromic film, Vertical Multileaf Collimator of penumbra size for all irradiation shape was smaller than lead block of those size that 2.0~3.5 mm for Co-60 gamma-ray, 0.5~1.0 mm for 6 MV X-ray. The results from this study, radiation treatment volume that results in shielding block can be minimized. In addition, during radiation treatment for 2, 3-dimensional radiation therapy using a Vertical Multileaf Collimator of this survey can be used to determine variety of irradiation fields.
담관 침범을 동반한 저혈관성 간세포암종에서 경동맥화학색전술, 정위 체부 방사선 치료, sorafenib을 병합하여 부분관해를 경험한 1예
황상연 ( Sang Youn Hwang ),이선미 ( Seon Mi Lee ),임정우 ( Jung Woo Im ),김준석 ( Joon Suk Kim ),안상부 ( Sang Bu Ahn ),지은경 ( Eun Kyeong Ji ),최철원 ( Chul Won Choi ),양광모 ( Gwang Mo Yang ) 대한간암학회 2013 대한간암학회지 Vol.13 No.2
Hepatocellular carcinoma (HCC) patients with bile duct invasion have a poor prognosis because many do not receive effective treatment. Surgical resection is thought to be only option of curative treatment, increasing chance of survival, but it is possible to minor group of patients because of poor reserved liver function associated with underlying liver disease and obstructive jaundice. Therefore many clinicians or centers still select locoregional therapy such as transarterial chemoembolization (TACE), radiation therapy (RT) etc. Stereotactic body radiation therapy (SBRT) is new technology providing very highly conformal ablative radiation dose for a small numbers (1-5 fractions) of large fraction size and is expected to salvage modality for HCC showed incomplete response of TACE due to vascularity or accessibility of feeding artery. Based on above suggestions, we herein offer our experience of a patient with partial remission of tumor by combination therapy of TACE, SBRT and sorafenib. Further study, maybe regarding a combination of locoregional and systemic therapy (so called multidisciplinary approach), is necessary on how to manage HCC patients with bile duct invasion or sparse vascularity.
부신, 폐전이를 동반한 거대 간세포암 환자에서 경동맥 화학색전술, 방사선 치료, sorafenib을 병합하여 간내암과 부신전이의 완전관해를 경험한 1예
황상연 ( Sang Youn Hwang ),이선미 ( Seon-mi Lee ),임정우 ( Jung Woo Im ),김준석 ( Joon Suk Kim ),안상부 ( Sang Bu Ahn,),지은경 ( Eun Kyeong Ji ),최철원 ( Chul Won Choi ),양광모 ( Gwang-mo Yang ) 대한간암학회 2013 대한간암학회지 Vol.13 No.1
Extrahepatic metastasis (EHM) associated with hepatocellular carcinoma (HCC) has been increasing due to prolonged survival with recent advances in therapeutic approaches including locoregional therapy such as transarterial chemoemoblization (TACE), radiofrequency ablation and radiation therapy (RT). Though many guidelines recommended systemic therapy such as sorafenib in this situation, some clinicians or centers still select locoregional therapy because the survival improvement of 2 or 3 months by sorafenib is far from optimal. Moreover, some studies showed that complete and partial response of intrahepatic tumors can result in significant improvement of patient survival even in situation of EHM. Based on above suggestions, we herein offer our experience of a patient with complete remission of intrahepatic tumor and adrenal gland metastasis treated with combination therapy of TACE and RT and sorafenib. Further study, maybe regarding a combination of locoregional and systemic therapy (so called multidisciplinary approach), is necessary on how to manage HCC patients with EHM.
주문맥혈전증을 동반한 거대 간세포암 환자에서 정위 체부 방사선치료와 sorafenib 병합으로 종양의 완전관해 유도 후 위궤양천공이 발생한 1예
황상연 ( Sang Youn Hwang ),이선미 ( Seon Mi Lee ),임정우 ( Jung Woo Im ),김준석 ( Joon Suk Kim ),안상부 ( Sang Bu Ahn ),지은경 ( Eun Kyeong Ji ),최철원 ( Chul Won Choi ),양광모 ( Gwang Mo Yang ) 대한간암학회 2014 대한간암학회지 Vol.14 No.1
Hepatocellular carcinoma (HCC) patients with main portal vein invasion have a poor prognosis associated with a median survival time of 2.7 months. Though many guidelines recommended sorafenib in HCC patients with macrovascular invasion (MVI), many clinicians or centers still select locoregional therapy (LRT) such as transarterial chemoembolization (TACE), radiation therapy (RT), or combination with LRT and sorafenib because the survival improvement by sorafenib only is expected to be shorter than that without MVI. However this multidisciplinary approach may increase treatment related toxicity such as liver failure etc. Stereotactic body radiation therapy (SBRT) is new technology providing very highly conformal ablative radiation dose for a small numbers (3-5 fractions) of large fraction size and is expected to new effective modality for HCC with MVI. Based on above suggestions, we herein offer our experience of a patient with perforation of radiation induced gastric ulcer after complete remission of tumor and main portal vein thrombosis by combination therapy of SBRT and sorafenib. Further study, maybe regarding a combination of locoregional and systemic therapy, is necessary on how to manage HCC patients with main portal vein invasion.
반복적인 경동맥 화학색전술 후 대혈관 침범으로 재발한 간세포암에 대해 정위체부방사선치료로 완전관해를 경험한 1예
황상연 ( Sang Youn Hwang ),이선미 ( Seon-mi Lee ),임정우 ( Jong Woo Im ),전기정 ( Ki Jeong Jeon ),안상부 ( Sang Bu Ahn ),지은경 ( Eun Kyeong Ji ),박진영 ( Jin-young Park ),최철원 ( Cheol-won Choi ),양광모 ( Gwang-mo Yang ) 대한간암학회 2016 대한간암학회지 Vol.16 No.2
Transarterial chemoembolization (TACE) is the worldwide procedure performed for patients with various stage hepatoceullar carcinoma (HCC), but is not yet considered as curative treatment because of relatively high local recurrence rate. Moreover, many clinicians frequently experience treatment failure (incomplete necrosis or stage progression etc.) after repeated TACE, but no clear guidelines have been recommended about salvage treatment modalities for this situation. Recently, studies for combination of radiation therapy and TACE for HCC with TACE refractoriness have been tried and reported better therapeutic efficacy. Based on above suggestions, we herein offer our experience of a patient with macrovascular invasion developed after repeated TACE that achieve complete remission by stereotactic body radiation therapy. Further study, maybe regarding a combination of locoregional and systemic therapy, is necessary on how to manage HCC patients with TACE refractoriness. (J Liver Cancer 2016;16:123-128)
주문맥침범과 임파절 전이를 동반한 Child 등급 B인 간세포암 환자에서 방사선치료와 sorafenib 병합으로 종양의 부분관해를 경험한
황상연 ( Sang Youn Hwang ),이선미 ( Seon Mi Lee ),임정우 ( Jung Woo Im ),김준석 ( Joon Suk Kim ),안상부 ( Sang Bu Ahn ),지은경 ( Eun Kyeong Ji ),강현철 ( Hyun Cheol Kang ),최철원 ( Cheol Won Choi ),양광모 ( Gwang Mo Yang ) 대한간암학회 2014 대한간암학회지 Vol.14 No.2
Reserved liver function is one of the most important determinants of survivial in advanced hepatocellular carcinoma (HCC). Especially in cirrhotic patient with decompensated liver function, sorafenib for HCC with main portal vein invasion have limited efficacy and survival benefit. Therefore many clinicians or centers still try locoregional therapy (LRT) such as transarterial chemoembolization (TACE), radiation therapy (RT), or combination with LRT and sorafenib in this situation. However this multidisciplinary approach may increase treatment related toxicity such as liver failure, etc. Recently, studies for combination of RT and sorafenib for HCC with portal vein invasion have been tried and reported not only bettertherapeutic efficacy, but also more hepatic toxicity.Based on above suggestions, we herein offer our experience of a patient that although achieved survival gain via partial remission of intrahepatic tumor and main portal vein thrombosis and metastatic lymph node by combination therapy of RT and sorafenib, finally expired due to hepatictoxicity. Further study, maybe regarding a combination of locoregional and systemic therapy, is necessary on how to manage decompenstated cirrhotic patients with HCC with main portal vein invasion. (J Liver Cancer 2014;14:120-126)
시뮬레이션 모델 및 내부수익율 분석을 통한 공정배치 개선에 관한 연구
조중현,양광모,전현정,강경식 明知大學校 産業技術硏究所 2005 産業技術硏究所論文集 Vol.24 No.-
Today, territory that can appear inflecting simulation is very many. In this paper, J enterprise did time analysis that use simulation about the several alternatives hearing example. And then Through economic analysis, save internal rate of return. Offer research that use the sequence and looks for the best alternative.